Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Thrombocythemia, Essential 2Polycythemia Vera 2Primary Myelofibrosis 1

Interventions

fludarabine phosphate 18Cyclophosphamide 16Peripheral Blood Stem Cell Transplantation 12Whole-Body Irradiation 11Busulfan 11Tacrolimus 10Mycophenolic Acid 10ruxolitinib 9fludarabine 7Methotrexate 6Cyclosporine 6Radiotherapy 5Aspirin 5Prednisone 4Melphalan 4Imatinib Mesylate 4Biopsy 4Antilymphocyte Serum 4peginterferon alfa-2a 3givinostat hydrochloride 3givinostat 3Stem Cell Transplantation 3Specimen Handling 3Decitabine 3bomedemstat 2Thiotepa 2Surveys and Questionnaires 2N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide 2Methylprednisolone 2Lenalidomide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Polycythemia Vera × bomedemstat × Clear all
NCT05558696 2026-05-07

IMG-7289-CTP-203

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
20 enrolled 19 charts
Myeloid

Polycythemia Vera

NCT04262141 2026-01-07

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

University of Miami

Phase 2 Active not recruiting
4 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential

Data powered by HemOnc (CC BY 4.0) Colophon âš¡